Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors.


Journal

RSC chemical biology
ISSN: 2633-0679
Titre abrégé: RSC Chem Biol
Pays: England
ID NLM: 101768727

Informations de publication

Date de publication:
02 Dec 2021
Historique:
received: 16 03 2021
accepted: 21 08 2021
entrez: 3 1 2022
pubmed: 4 1 2022
medline: 4 1 2022
Statut: epublish

Résumé

Mouse double minute 2 homolog (MDM2, Hdm2) is an important negative regulator of the tumor suppressor p53. Using a mRNA based display technique to screen a library of >10

Identifiants

pubmed: 34977581
doi: 10.1039/d1cb00056j
pii: d1cb00056j
pmc: PMC8637822
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1661-1668

Informations de copyright

This journal is © The Royal Society of Chemistry.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54
pubmed: 23946421
Signal Transduct Target Ther. 2020 Sep 23;5(1):213
pubmed: 32968059
Science. 1996 Nov 8;274(5289):948-53
pubmed: 8875929
Nat Chem. 2017 Aug;9(8):762-771
pubmed: 28754949
Bioconjug Chem. 2019 Feb 20;30(2):400-404
pubmed: 30616339
Chemistry. 2021 Jan 21;27(5):1487-1513
pubmed: 32875673
Cancer Cell. 2012 Jan 17;21(1):25-35
pubmed: 22264786
Angew Chem Int Ed Engl. 2015 Feb 2;54(6):1950-3
pubmed: 25521313
ACS Chem Biol. 2016 Jun 17;11(6):1624-30
pubmed: 27027149
Curr Med Chem. 2020;27(22):3706-3734
pubmed: 31223076
Biopolymers. 2016 Nov;106(6):853-863
pubmed: 27287767
ACS Chem Biol. 2013 Feb 15;8(2):297-302
pubmed: 23151250
Biomed Pharmacother. 2018 Dec;108:1090-1096
pubmed: 30372809
J Am Chem Soc. 2013 Apr 10;135(14):5433-40
pubmed: 23506421
J Med Chem. 2015 Aug 27;58(16):6348-58
pubmed: 26181851
J Am Chem Soc. 2018 Nov 28;140(47):15986-15996
pubmed: 30384589
ACS Chem Biol. 2021 Feb 19;16(2):414-428
pubmed: 33533253
Chem Sci. 2016 Jun 1;7(6):3785-3790
pubmed: 30155020
Curr Opin Chem Biol. 2017 Jun;38:141-147
pubmed: 28570865
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
J Med Chem. 2019 Nov 27;62(22):10098-10107
pubmed: 31657556
Traffic. 2007 Jul;8(7):848-66
pubmed: 17587406
ACS Cent Sci. 2020 Oct 28;6(10):1753-1761
pubmed: 33145412
RSC Chem Biol. 2020 Oct 20;1(5):405-420
pubmed: 34458771
Clin Cancer Res. 2021 Jul 22;:
pubmed: 34301750
Angew Chem Int Ed Engl. 2018 Feb 23;57(9):2314-2333
pubmed: 28913971
ChemMedChem. 2019 Jul 17;14(14):1305-1314
pubmed: 31066983
Future Med Chem. 2020 Aug;12(15):1431-1446
pubmed: 32723097
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4665-70
pubmed: 19255450
Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11801-11805
pubmed: 31251434
Nat Protoc. 2011 Jun;6(6):779-90
pubmed: 21637198
Angew Chem Int Ed Engl. 2015 Jun 15;54(25):7328-31
pubmed: 25925500
Chem Rev. 2019 Sep 11;119(17):10360-10391
pubmed: 30395448
Curr Opin Biotechnol. 2017 Dec;48:242-250
pubmed: 28783603
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677

Auteurs

Anselm F L Schneider (AFL)

Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10 Berlin 13125 Germany hackenbe@fmp-berlin.de.

Joerg Kallen (J)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Johannes Ottl (J)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Patrick C Reid (PC)

PeptiDream, 3-25-23 Tonomachi Kawasaki-Ku Kanagawa 210-0821 Japan.

Sebastien Ripoche (S)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Stephan Ruetz (S)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Therese-Marie Stachyra (TM)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Samuel Hintermann (S)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Christoph E Dumelin (CE)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Christian P R Hackenberger (CPR)

Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10 Berlin 13125 Germany hackenbe@fmp-berlin.de.
Humboldt Universität zu Berlin, Institut für Chemie, Brook-Taylor-Str. 2 Berlin 12489 Germany.

Andreas L Marzinzik (AL)

Novartis Institutes for BioMedical Research, Novartis Campus Basel CH-4056 Switzerland andreas.marzinzik@novartis.com.

Classifications MeSH